Logo image of CMMB

CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Price, Quote, News and Overview

NASDAQ:CMMB - Nasdaq - US16385C1045 - ADR - Currency: USD

1.4  +0.03 (+2.56%)

CMMB Quote, Performance and Key Statistics

CHEMOMAB THERAPEUTICS LTD

NASDAQ:CMMB (5/27/2025, 5:26:57 PM)

1.4

+0.03 (+2.56%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2.55
52 Week Low0.78
Market Cap26.40M
Shares18.86M
Float709.76K
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-19 2025-08-19
IPO08-14 2012-08-14


CMMB short term performance overview.The bars show the price performance of CMMB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20

CMMB long term performance overview.The bars show the price performance of CMMB in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 -40

The current stock price of CMMB is 1.4 USD. In the past month the price increased by 4.48%. In the past year, price increased by 30.85%.

CHEMOMAB THERAPEUTICS LTD / CMMB Daily stock chart

CMMB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.08 328.06B
AMGN AMGEN INC 13.46 150.26B
GILD GILEAD SCIENCES INC 14.09 135.70B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.53B
REGN REGENERON PHARMACEUTICALS 13.61 65.13B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.83B
ARGX ARGENX SE - ADR 98.77 35.40B
ONC BEIGENE LTD-ADR 6.1 25.76B
BNTX BIONTECH SE-ADR N/A 23.69B
NTRA NATERA INC N/A 21.46B
SMMT SUMMIT THERAPEUTICS INC N/A 19.04B
BIIB BIOGEN INC 8.12 18.81B

About CMMB

Company Profile

CMMB logo image Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Company Info

CHEMOMAB THERAPEUTICS LTD

Kiryat Atidim, Building 7

TEL AVIV-YAFO 02139 IL

CEO: Neil Cohen

Employees: 16

CMMB Company Website

CMMB Investor Relations

Phone: 972773310156

CHEMOMAB THERAPEUTICS LTD / CMMB FAQ

What is the stock price of CHEMOMAB THERAPEUTICS LTD today?

The current stock price of CMMB is 1.4 USD. The price increased by 2.56% in the last trading session.


What is the ticker symbol for CHEMOMAB THERAPEUTICS LTD stock?

The exchange symbol of CHEMOMAB THERAPEUTICS LTD is CMMB and it is listed on the Nasdaq exchange.


On which exchange is CMMB stock listed?

CMMB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CHEMOMAB THERAPEUTICS LTD stock?

9 analysts have analysed CMMB and the average price target is 9.18 USD. This implies a price increase of 555.71% is expected in the next year compared to the current price of 1.4. Check the CHEMOMAB THERAPEUTICS LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CHEMOMAB THERAPEUTICS LTD worth?

CHEMOMAB THERAPEUTICS LTD (CMMB) has a market capitalization of 26.40M USD. This makes CMMB a Nano Cap stock.


How many employees does CHEMOMAB THERAPEUTICS LTD have?

CHEMOMAB THERAPEUTICS LTD (CMMB) currently has 16 employees.


What are the support and resistance levels for CHEMOMAB THERAPEUTICS LTD (CMMB) stock?

CHEMOMAB THERAPEUTICS LTD (CMMB) has a support level at 1.34 and a resistance level at 1.43. Check the full technical report for a detailed analysis of CMMB support and resistance levels.


Should I buy CHEMOMAB THERAPEUTICS LTD (CMMB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CHEMOMAB THERAPEUTICS LTD (CMMB) stock pay dividends?

CMMB does not pay a dividend.


When does CHEMOMAB THERAPEUTICS LTD (CMMB) report earnings?

CHEMOMAB THERAPEUTICS LTD (CMMB) will report earnings on 2025-08-19.


What is the Price/Earnings (PE) ratio of CHEMOMAB THERAPEUTICS LTD (CMMB)?

CHEMOMAB THERAPEUTICS LTD (CMMB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.29).


What is the Short Interest ratio of CHEMOMAB THERAPEUTICS LTD (CMMB) stock?

The outstanding short interest for CHEMOMAB THERAPEUTICS LTD (CMMB) is 17.3% of its float. Check the ownership tab for more information on the CMMB short interest.


CMMB Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to CMMB. When comparing the yearly performance of all stocks, CMMB is one of the better performing stocks in the market, outperforming 72.73% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CMMB Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CMMB. While CMMB seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CMMB Financial Highlights

Over the last trailing twelve months CMMB reported a non-GAAP Earnings per Share(EPS) of -0.29. The EPS increased by 96.73% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -82.2%
ROE -103.01%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%97.5%
Sales Q2Q%N/A
EPS 1Y (TTM)96.73%
Revenue 1Y (TTM)N/A

CMMB Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to CMMB. The Buy consensus is the average rating of analysts ratings from 9 analysts.


Ownership
Inst Owners16.69%
Ins Owners10.03%
Short Float %17.3%
Short Ratio0.97
Analysts
Analysts84.44
Price Target9.18 (555.71%)
EPS Next Y29.62%
Revenue Next YearN/A